Efficacy of immunoglobulin G (IgG) bearing liposomal amphotericin B (LAMB-IgG), liposomal amphotericin B without IgG (LAMB) or free amphotericin B (fAMB/Fungizone) was investigated in the treatment of systemic candidiasis in a neutropenic mouse model. Treatment with a single dose (0.6 or 0.9 mg amphotericin B per kg body weight) of LAMB-IgG resulted in a significant increase in the survival rate of neutropenic mice infected with 3×105 cfu ofCandida albicans compared to untreated controls, mice injected with IgG, or liposome alone. Survival was also better in neutropenic mice treated with LAMB-IgG than in neutropenic mice treated with the same dose of LAMB or fAMB. Moreover, 65% of all mice survived the infection after treatment with a single dose of 0.6 mg AMB of the LAMB-IgG formulation. Quantitative culture counts of organs showed that both fAMB and LABM-IgG formulations even at a dose of 0.3 mg AMB/kg, clearedC. albicans from the spleens, livers, and lungs but not from the kidneys. However, a decreasd number ofC. albicans cells was recovered from the kidneys of mice that survived the infection. Results of the study suggest that LAMB-IgG is more effective than LAMB or fAMB in the therapy of disseminated candidiasis in neutropenic mice.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Armstrong D. Life-threatening opportunistic fungal infections in patients with the acquired immunodeficiency syndrome. Ann NY Acad Sci 1988; 544: 443–50.
Bodey GP. Fungal infections in cancer patients. Ann NY Sci 1988; 544: 431–42.
Bodey GP. Candidiasis in cancer patients. Am J Med 1984; 77(4D): 13–19.
Mirskey HS, Cuttner J. Fungal infections in acute leukemia. Cancer 1972; 30: 348–352.
Myers JD, Atkinson K. Infection in bone marrow transplantation. Haematology 1983; 12: 791–811.
Lopez-Berestein G, Hopfer RL, Mehta R, Mehta K, Hersch EM, Juliano RL. Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J Infect Dis 1984; 150: 278–83.
Taylor RL, Williams DM, Craven PC, Graybill JR, Drutz DJ, Magee WE. Amphotericin B in liposomes: A novel therapy for histoplasmosis. Am Rev Respir Dis 1982; 125: 610–11.
Graybill JR, Craven PC, Taylor RL, Williams DM, Magee WE. Treatment of murine cryptococcosis with liposome-associated amphotericin B J Infect Dis 1982; 145: 748–52.
Lopez-Brestein G. Treatment of systemic fungal infections with liposomal amphotericin B. In Lopez-Berestein G, Fidler IJ (eds.), Liposomes in the Therapy of Infections, Diseases, and Cancer. New York: Alan R Liss, 1988: 317–327.
Ostro MJ, Cullis PR. Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm 1989; 46: 1576–87.
Sculier J-P, Coune A, Meunier F, Brassinne C, Laduron C, Hollaert C, Collette N, Heymans C, Klastersky J. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Exp J Cancer Clin Oncol 1988; 24: 527–38.
Mehta R, Lopez-Berestein G, Hopfer R, Mills K, Juliano RL. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta 1984; 770: 230–34.
Szoka Jr FC, Milholland D, Barza M. Effect of lipid composition and liposome size on toxicity and in viro fungicidal activity of liposome-intercalated amphotericin B. Antimicro Agents Chemther 1987; 31: 421–29.
Leserman LD, Machy P, Barbet J. Covalent coupling of monoclonal antibodies and protein A to liposomes: Specific interaction with cells in vitro and in vivo. In Gregoriadis G. (ed.), Liposome Technology, Vol. 3: Targeted Drug Delivery and Biological Interaction. Boca Raton, Florida: CRC Press, 1984: 29–40.
Shen D, Huang A, Huang L. An improved method for covalent attachment of antibody to liposomes. Biochim Biophys Acta 1988; 689: 31–37.
Hospenthal D, Gretzinger K, Rogers A. Treatment of a murine model of systemic candidiasis with liposomal amphotericin B bearing antibody toCandida albicans. J Med Microbiol 1989; 30: 193–97.
Hospenthal DR, Rogers AL, Beneke ES. Effect of attachment of anticandidal antibody to the surface of liposomes encapsulating amphotericin B in the treatment of murine candidiasis. Antimicrob Agents Chemother 1989; 33: 16–18.
Dromer F, Barbet J, Bolard J, Charriere J, Yeni P. Improvement of amphotericin B activity during experimental cryptococcosis by incorporating into immunoliposomes. Antimicrob Agents Chemther 1990; 34: 2055–60.
McKinney MM, Parkinson A. A simple, non-chromatographic procedure to purify immunoglobulins from serum and ascites fluid. J Immunol Methods 1987; 96: 271–78.
Hospenthal DR, Rogers AL, Mills GL. Development of amphotericin B liposomes bearing antibodies specific toCandida albicans. Mycopathologia 1988; 101: 37–45.
Belay, T, Hospenthal D, Rogers A, Patterson MJ. Med Vet Mycol.
Gehan EA. A generalized Wilcoxon test for comparin arbitrarily single-censored sample. Biometrika 1965; 52: 20–217.
Clark MJ, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman R. Bonner DP. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemther 1991; 35: 615–21.
About this article
Cite this article
Belay, T., Hospenthal, D.R., Rogers, A.L. et al. Treatment of systemic candidiasis in a neutropenic murine model using immunoglobulin G bearing liposomal amphotericin B. Mycopathologia 123, 9–17 (1993). https://doi.org/10.1007/BF01103483
- Free amphotericin B
- Immunoglobulin G
- Liposomal amphotericin B
- Systemic candidiasis